Entrada Therapeutics, Inc. (TRDA)
Develops genetic medicines that deliver drugs inside cells to treat neuromuscular and eye diseases.
$5.83-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+0.5%
The outlook
TRDA trades at $5.83, well below both its 50- and 200-day moving averages, sitting near its 52-week low. Analyst coverage is sparse but strongly positive, with an average price target implying roughly 222% upside from current levels. The stock's positioning near the bottom of its yearly range contrasts sharply with analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Price targetAvg target +222% vs current price
Analyst price target
~12-month · 4 analysts$18.75average target+221.6% vs now
Now $5.83
Low $10.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$226.3M
52-wk high
$16.45
52-wk low
$4.93
50-day avg
$6.73
200-day avg
$9.63
Trailing P/E
—